Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Dandoy, Christopher E  [Clear All Filters]
2024
Klages KL, Schwartz LE, Crabtree EJSantee, Brokamp C, Rasnick E, Dandoy CE, Davies SM, Pai ALH. Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant. Pediatr Blood Cancer. 2024:e30892.
2023
Wang YZMichele, Taggart CB, Huber JF, Davies SM, Smith DF, Hogenesch JB, Dandoy CE. Daytime-restricted parenteral feeding is associated with earlier oral intake in children following stem cell transplant. J Clin Invest. 2023;133(4).
Dunseath C, Connor GO', Mahulkar S, Badia P, Koo J, Dandoy CE. Incidence of bloodstream infections after hematopoietic stem cell transplant for Hurler Syndrome. Transplant Cell Ther. 2023.
Koo J, Ziady AG, Reynaud D, Abdullah S, Luebbering N, Kahn S, Langenberg L, Strecker L, Lake K, Dandoy CE, et al. Increased body mass index augments endothelial injury and clinical outcomes after hematopoietic stem cell transplant: Higher BMI increases endothelial injury after BMT. Transplant Cell Ther. 2023.
Sabulski A, Abdullah S, Luebbering N, Aunins B, Castillo C, Lake K, Duell A, Strecker L, Langenberg L, Broomhead W, et al. Mechanisms of endothelial injury and transplant-associated thrombotic microangiopathy in tandem autologous hematopoietic stem cell transplant for neuroblastoma. Haematologica. 2023.
Schoettler ML, Lehmann LElaine, Kao P-C, Chen N, Jodele S, Chonat S, Williams KM, London WB, Duncan C, Dandoy CE. Pediatric Transplant Associated Thrombotic Microangiopathy Healthcare Utilization and Implications of Eculizumab Therapy. Blood Adv. 2023.
Jodele S, Dandoy CE, Aguayo-Hiraldo P, Lane A, Teusink-Cross A, Sabulski A, Mizuno K, Laskin BL, Freedman JLawrence, Davies SM. Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA. Blood. 2023.
2022
Bhatt NS, Sharma A, St Martin A, Abid MBilal, Brown VI, Diaz MA, Frangoul H, Gadalla SM, Herr MM, Krem MM, et al. Clinical Characteristics and Outcomes of COVID-19 in Pediatric and Early Adolescent and Young Adult Haematopoietic Stem Cell Transplant Recipients: A Cohort Study. Transplant Cell Ther. 2022.
Mizuno K, Dandoy CE, Teusink-Cross A, Davies SM, Vinks AA, Jodele S. Eculizumab precision dosing algorithm for thrombotic microangiopathy in children and young adults undergoing HSCT. Blood Adv. 2022.
Bender JD, Del Toro HOquendo-, Benoit J, Howell JC, Badia P, Davies SM, Grimley MS, Jodele S, Phillips C, Burns K, et al. Reduced Intensity Conditioning Mitigates Risk for Primary Ovarian Insufficiency but Does Not Decrease Risk for Infertility in Pediatric and Young Adult Survivors of Hematopoietic Stem Cell Transplant: Gonadal Toxicity and Fertility Following Pediatric HSC. Transplant Cell Ther. 2022.
Koo J, Auletta JJ, Hartley DM, Huber J, Jaglowski S, Kapadia M, Kusnier K, Lehmann L, Maakaron J, Myers KC, et al. Secondary impact of the COVID-19 pandemic on patients and the cell therapy healthcare ecosystem. Transplant Cell Ther. 2022.
2021
Hord JD, Dandoy CE. Are we certain that chlorhexidine gluconate bathing is not beneficial in reducing central line associated blood stream infections among children with cancer or undergoing hematopoietic stem cell transplantation?. Cancer. 2021.
Singh A, Dandoy CE, Chen M, Kim S, Mulroney CM, Kharfan-Dabaja MA, Ganguly S, Maziarz RT, Kanakry CG, Kanakry JA, et al. Post-Transplant cyclophosphamide is associated with increase in Non-CMV Herpesvirus infections in Acute leukemia and MDS patients. Transplant Cell Ther. 2021.
2020
Hsu JW, Shaw BE, Kim S, Logan BR, Sees JA, Confer DL, Pulsipher MA, Shah N, Switzer GE, Abidi MH, et al. Collection of Peripheral Blood Progenitor Cells in One Day is Associated with Decreased Donor Toxicity compared to Two Days in Unrelated Donors. Biol Blood Marrow Transplant. 2020.
Arnold SD, Brazauskas R, He N, Li Y, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, et al. The impact of donor type on outcomes and cost of allogeneic hematopoietic cell transplant for pediatric leukemia: a merged CIBMTR and PHIS analysis: Pediatric acute leukemia transplant risks and utilization. Biol Blood Marrow Transplant. 2020.
Dandoy CE, Kim S, Chen M, Ahn KWoo, Ardura MI, Brown V, Chhabra S, Díaz MÁngel, Dvorak C, Farhadfar N, et al. Incidence, Risk Factors, and Outcomes of Patients Who Develop Mucosal Barrier Injury-Laboratory Confirmed Bloodstream Infections in the First 100 Days After Allogeneic Hematopoietic Stem Cell Transplant. JAMA Netw Open. 2020;3(1):e1918668.
Jodele S, Medvedovic M, Luebbering N, Chen J, Dandoy CE, Laskin BL, Davies SM. Interferon-complement loop in transplant-associated thrombotic microangiopathy. Blood Adv. 2020;4(6):1166-1177.
Algwaiz G, Aljurf M, Koh M, Horowitz MM, Ljungman P, Weisdorf D, Saber W, Kodera Y, Szer J, Jawdat D, et al. Real-world issues and potential solutions in HCT during the COVID-19 pandemic: Perspectives from the WBMT and the CIBMTR's Health Services and International Studies Committee. Biol Blood Marrow Transplant. 2020.
2019
Sampson M, Hickey V, Huber J, Alonso PBadia, Davies SM, Dandoy CE. Feasibility of continuous temperature monitoring in pediatric immunocompromised patients: A pilot study. Pediatr Blood Cancer. 2019:e27723.
Bhandari R, Orgel E, Rushing T, Malicse K, Evangelista V, Jodele S, Dandoy CE. Improving the Timeliness of Chemotherapy Administration in the Bone Marrow Transplant Unit. Biol Blood Marrow Transplant. 2019.
Laskin BL, Denburg MR, Furth SL, Moatz T, Altrich M, Kleiboeker S, Lutzko C, Zhu X, Blackard JT, Jodele S, et al. The natural history of BK polyomavirus and the host immune response after stem cell transplantation. Clin Infect Dis. 2019.
Badia P, Hickey V, Flesch L, Byerly M, Sensibaugh C, Potts K, Michel C, Drozd A, Curd F, Crosby L, et al. Quality Improvement Initiative to Reduce Nighttime Noise in a Transplantation and Cellular Therapy Unit. Biol Blood Marrow Transplant. 2019.
2018
Romick-Rosendale LE, Haslam DB, Lane A, Denson L, Lake K, Wilkey A, Watanabe M, Bauer S, Litts B, Luebbering N, et al. Antibiotic Exposure and Reduced Short Chain Fatty Acid Production after Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2018.
2016
Khandelwal P, Emoto C, Fukuda T, Vinks AA, Neumeier L, Dandoy CE, El-Bietar J, Chandra S, Davies SM, Bleesing JJ, et al. A Prospective Study of Alemtuzumab as a Second Line Agent for Steroid Refractory Acute Graft Versus Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplant. Biol Blood Marrow Transplant. 2016.
Jodele S, Dandoy CE, Danziger-Isakov L, Myers KC, El-Bietar J, Nelson A, Wallace G, Teusink-Cross A, Davies SM. Terminal complement blockade after HSCT is safe without meningococcal vaccination. Biol Blood Marrow Transplant. 2016.